Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,107.12 +103.66 (+10.33%)

Official Closing Price Updated: 4:10 PM EST, Feb 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Can This Stock Double Again in 2026? ↗

January 11, 2026

It's a tough act to follow.

Via The Motley Fool

Is the Schwab U.S. Dividend Equity ETF a Buy Now? ↗

January 11, 2026

It's time to start thinking strategically -- and even philosophically -- about how seemingly similar funds are actually quite different.

Via The Motley Fool

Topics ETFs Stocks

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

This Healthcare Stock Could Be One of the Best Companies to Own in 2026 ↗

January 11, 2026

It has strong momentum thanks to its current portfolio and several catalysts on the horizon.

Via The Motley Fool

Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?

January 09, 2026

Novo Nordisk shares inch higher as the pharma giant announces an oral Wegovy partnership with Amazon Pharmacy. Here’s why NVO stock is worth owning at current levels.

Via Barchart.com

Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 09, 2026

In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive...

Via MarketMinute

Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge

January 09, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by...

Via MarketMinute

The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance

January 09, 2026

As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company...

Via MarketMinute

Topics Economy

The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)

January 09, 2026

As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic...

Via PredictStreet

Topics Earnings Economy Intellectual Property

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

January 09, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its...

Via MarketMinute

Topics Intellectual Property

The WeightWatchers Rebirth: A Clinical Transformation and the GLP-1 Era

January 09, 2026

As of January 9, 2026, WW International, Inc. (NASDAQ: WW), better known as WeightWatchers, stands at the most pivotal juncture in its 63-year history. After a tumultuous 2024 and 2025 that saw the...

Via PredictStreet

Topics Artificial Intelligence Bankruptcy

Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight ↗

January 09, 2026

Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz alone in a late-stage trial.

Via Benzinga

The Great Rotation: Investors Pivot to Defensive Moats as Tech Giants Face 'AI ROI' Audit

January 08, 2026

As the first full trading week of 2026 comes to a close, a seismic shift is rattling Wall Street. The high-flying technology sector, which dominated the market narrative throughout 2024 and 2025, is...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value

January 08, 2026

The tech-heavy Nasdaq Composite faced a stark reversal on January 8, 2026, as a wave of profit-taking in high-flying artificial intelligence stocks, led by Nvidia (NASDAQ: NVDA), dragged the index...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

U.S. Trade Deficit Plummets to 2009 Levels as 'Liberation Day' Tariffs and Gold Surge Reshape Global Trade

January 08, 2026

On January 8, 2026, the U.S. Bureau of Economic Analysis and the Census Bureau released a landmark report revealing that the nation’s trade deficit has narrowed to its lowest level since the height of...

Via MarketMinute

Topics Economy Supply Chain World Trade

Apple Shares Retreat 7% as Memory Cost Surge and 'Great Rotation' Reset Tech Valuations

January 08, 2026

The start of 2026 has brought a cold front to Silicon Valley as Apple Inc. (NASDAQ:AAPL) shares retreated 7% from their December all-time highs. This downturn, which has wiped out over $200 billion in...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Via MarketMinute

Topics Intellectual Property

Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today ↗

January 08, 2026

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.

Via Stocktwits

Topics ETFs Government Stocks

Ventyx’s $1.2B Buyout By Eli Lilly Proves Timing Often Beats Conviction In Biotech Investing — A VC Explains ↗

January 07, 2026

Bottom buyers saw over 2,000% gains, while IPO investors merely broke even after a 90% drawdown, according to Atlas Venture’s Bruce Booth.

Via Stocktwits

Topics Initial Public Offering

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

January 07, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine ↗

January 07, 2026

Eli Lilly's plan to buy Ventyx for $1.2 billion benefits more than the takeover target, an analyst said Thursday.

Via Investor's Business Daily

Eli Lilly Confirms Plan To Buy Ventyx Biosciences In $1.2 Billion Deal ↗

January 07, 2026

Eli Lilly confirmed its $1.2 billion plan late Wednesday to acquire Ventyx Biosciences. Ventyx stock ran up nearly 40%.

Via Investor's Business Daily

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

Via MarketMinute

Topics Economy

Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal ↗

January 07, 2026

Lilly will acquire all of the outstanding shares of Ventyx for $14 per share of common stock in an all-cash transaction.

Via Stocktwits

3 Drug Stocks to Buy at a Discount ↗

January 07, 2026

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Via The Motley Fool

The Valuation Wall: Nasdaq Momentum Stalls as the 'Great Rotation' of 2026 Takes Hold

January 07, 2026

The relentless surge that propelled the technology sector to historic heights throughout 2024 and 2025 has hit a significant roadblock in the opening week of 2026. As of January 7, 2026, the tech-heavy...

Via MarketMinute

Topics Artificial Intelligence Economy

The Great Rotation: How the 2026 Market Rally Outgrew the 'Magnificent Seven'

January 07, 2026

As the first week of trading in 2026 comes to a close, the S&P 500 has once again shattered records, crossing the 7,500 threshold with a momentum that feels fundamentally different from the...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

This Could Be Key to Pfizer's Turnaround in 2026 ↗

January 07, 2026

Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Shares Surge On Report Of Potential Ventyx Acquisition ↗

January 07, 2026

Eli Lilly shares are trading higher Wednesday following a report suggesting the company is nearing a deal for Ventyx Biosciences.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.